[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Cadrenal Therapeutics, Inc. (CVKD) reports a proposed sale of 10,900 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $150,202 and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as founders' shares on 05/17/2022 from the issuer and the filer indicates payment was made on that date.

The filing also discloses three recent 10b5-1 sales by Matthew Szot totaling 3,500 shares for gross proceeds of $48,984.95, with trades dated 08/27/2025, 08/28/2025 and 09/24/2025. The filer certifies no undisclosed material adverse information and references a trading plan where applicable.

Positive

• Disclosure of broker and planned sale date via Morgan Stanley Smith Barney promotes transparency
• Use of 10b5-1 sales for recent insider trades indicates pre-arranged, rule-compliant dispositions

Negative

• Proposed sale of 10,900 founders' shares (aggregate value $150,202) increases share supply from an insider
• Recent insider sales totaling 3,500 shares for $48,984.95 may be perceived negatively by some investors

Insights

Securities Analyst

TL;DR: Insider founder shares being sold via broker and recent 10b5-1 trades increase share supply but follow planned procedures.

The filing shows a proposed sale of 10,900 founders' shares with a disclosed market value of $150,202 to be executed through Morgan Stanley Smith Barney on NASDAQ. Recent 10b5-1 sales by a named insider generated $48,984.95 in gross proceeds across three trades, indicating ongoing orderly dispositions rather than ad hoc block sales. For investors, the filing provides transparency on insider liquidity but does not include operational or financial performance details.

Corporate Governance Expert

TL;DR: The disclosure adheres to Rule 144 and notes reliance on 10b5-1 arrangements, supporting compliance and disclosure discipline.

The filer identifies the shares as founders' shares acquired from the issuer and furnishes broker and sale timing details consistent with Rule 144 requirements. The representation that no material nonpublic information is known and the reference to plan adoption dates (where applicable) are important for governance and insider trading controls. The filing is procedural and does not signal corporate governance changes or material corporate events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10900	150202.00	2046854	09/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			10900	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/24/2025	1500	20992.95
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/28/2025	400	5600.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Cadrenal Therapeutics (CVKD) disclose?

The form discloses a proposed sale of 10,900 common shares via Morgan Stanley Smith Barney with an aggregate market value of $150,202 and an approximate sale date of 09/25/2025 on NASDAQ.

Were recent insider sales disclosed for CVKD?

Yes. Three 10b5-1 sales by Matthew Szot on 08/27/2025, 08/28/2025, and 09/24/2025 totaling 3,500 shares for gross proceeds of $48,984.95 are reported.

What type of shares are being sold in the Form 144 for CVKD?

The filing states the shares are founders' shares acquired from the issuer on 05/17/2022.

Which broker is handling the proposed sale of CVKD shares?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filer assert possession of material nonpublic information?

By signing the notice, the person represents they do not know any material adverse information